N-Acetyl Cysteine and Reduced Time-to-Disease Progression

• A randomized controlled trial of N-acetylcysteine in the treatment of early-onset preeclampsia: Study Protocol.

  • 2026-06-17
  • RCT · n = 153
  • PloS one 21(6)
  • • Kehinde S Okunade
    • Adebola A Adejimi
    • Muisi A Adenekan
    • Iyabo Y Ademuyiwa
    • Hameed Adelabu
    • Fatimah M Habeebu-Adeyemi
    • Adaiah P Soibi-Harry
    • Ololade Onasanya
    • Ayomide I Fayinto
    • Temitope V Adekanye
    • Fatimah Adeboje-Jimoh
    • Oziegbe Oghide
    • Nosimot O Davies
    • Packson Akhenamen
    • Festus O Olowoselu
    • Babasola O Okusanya

  • PubMed: 42308185
  • DOI: 10.1371/journal.pone.0347695

  1 Insight on

  • Reduced Time-to-Disease Progression

  • High evidence
  • Large Human Trial
  • Pregnant Women

  The primary endpoint is the time-to-progression (in days) of early-onset preeclampsia to severe disease.

  Effect

  Neutral

  Effect size

  Small

  Significant

  No

  Dose

  600 mg daily